MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$6,098K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Payable-in-kind interest on cred...
Proceeds from issuance of common...
Accounts payable, accrued expens...
Others
Negative Cash Flow Breakdown
Net loss
Payment of principal of long-ter...
Offering costs for common stock ...
Payment of employee tax obligati...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-14,713
44,661
-30,911
-26,441
Depreciation
18
-168
75
151
Accretion of debt discount and amortization of financing costs
774
-681
440
743
Change in fair value of derivative liabilities
-394
6,838
-12,541
7,222
Stock-based compensation expense
358
-1,882
581
1,736
Payable-in-kind interest on credit agreement
3,409
-5,434
1
5,433
Accrued interest
-
-
0
0
Operating lease right-of-use assets
0
-186
82
160
Accounts receivable
-134
114
-17
-114
Inventory
-17
-2
-47
-173
Prepaid expenses and other current assets
-1,678
1,232
480
-673
Accounts payable, accrued expenses, due to related parties, and other current liabilities
1,833
3,254
-1,084
45
Operating lease liabilities
0
214
-96
-183
Net cash used in operating activities
-6,098
31,596
-18,787
-24,618
Purchases of equipment and leasehold improvements
0
0
0
0
Net cash from investing activities
0
0
0
0
Proceeds from issuance of common stock and warrants
3,109
-43,882
38,234
14,146
Payment of principal of long-term debt
304
8,108
-
-
Offering costs for common stock and warrants issuance
62
-1,334
686
806
Payment of employee tax obligations related to vesting restricted stock units
24
-17
16
1
Net cash provided by financing activities
2,719
-50,639
37,532
13,339
Net (decrease) in cash, cash equivalents and restricted cash
-3,379
-19,043
18,745
-11,279
Cash, cash equivalents and restricted cash, beginning of the period
37,320
37,320
29,854
-
Cash, cash equivalents and restricted cash, end of the period
13,801
-
-
-
Cash and cash equivalents
12,841
-
-
-
Restricted cash
960
-
-
-
Total cash and cash equivalents and restricted cash as presented above
13,801
17,180
37,320
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$3,109K
(-78.02%↓ Y/Y)
Net cash provided by
financing activities
$2,719K
(-79.62%↓ Y/Y)
Canceled cashflow
$390K
Net (decrease) in
cash, cash...
-$3,379K
(70.04%↑ Y/Y)
Canceled cashflow
$2,719K
Payable-in-kind interest on
credit agreement
$3,409K
(-37.25%↓ Y/Y)
Accounts payable,
accrued expenses, due to...
$1,833K
(3973.33%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,678K
(-149.33%↓ Y/Y)
Accretion of debt discount
and amortization of...
$774K
(4.17%↑ Y/Y)
Change in fair value of
derivative liabilities
-$394K
(-105.46%↓ Y/Y)
Stock-based compensation
expense
$358K
(-79.38%↓ Y/Y)
Accounts receivable
-$134K
(-17.54%↓ Y/Y)
Depreciation
$18K
(-88.08%↓ Y/Y)
Inventory
-$17K
(90.17%↑ Y/Y)
Payment of principal of
long-term debt
$304K
Offering costs for common
stock and warrants...
$62K
(-92.31%↓ Y/Y)
Payment of employee tax
obligations related to...
$24K
(2300.00%↑ Y/Y)
Net cash used in
operating activities
-$6,098K
(75.23%↑ Y/Y)
Canceled cashflow
$8,615K
Net loss
-$14,713K
(44.36%↑ Y/Y)
Buy us a coffee
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)